You are here

GSK shutting down Biopolis neural unit

Other ongoing investments here not affected; UK pharma giant remains committed to R&D in Singapore


IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.

While it...